C07K 2317/732
Antibody-dependent cellular cytotoxicity [adcc]
Official title: Antibody-dependent cellular cytotoxicity [ADCC]
C07K2317/732 (Antibody-dependent cellular cytotoxicity [adcc]) appears on 2,888 US grants and 5,537 published applications in this corpus.
Search patents in C07K- Granted patents
- 2,888
- Published applications
- 5,537
- Assignees
- 1,509
- Inventors
- 8,071
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1987 | 1 | 0 |
| 1988 | 0 | 0 |
| 1989 | 2 | 0 |
| 1990 | 3 | 0 |
| 1991 | 1 | 0 |
| 1992 | 2 | 0 |
| 1993 | 3 | 0 |
| 1994 | 1 | 0 |
| 1995 | 1 | 0 |
| 1996 | 10 | 0 |
| 1997 | 19 | 0 |
| 1998 | 18 | 0 |
| 1999 | 8 | 0 |
| 2000 | 11 | 0 |
| 2001 | 9 | 5 |
| 2002 | 11 | 18 |
| 2003 | 10 | 45 |
| 2004 | 10 | 50 |
| 2005 | 7 | 92 |
| 2006 | 10 | 78 |
| 2007 | 19 | 99 |
| 2008 | 44 | 107 |
| 2009 | 44 | 165 |
| 2010 | 77 | 159 |
| 2011 | 79 | 190 |
| 2012 | 95 | 160 |
| 2013 | 126 | 192 |
| 2014 | 127 | 239 |
| 2015 | 170 | 227 |
| 2016 | 165 | 292 |
| 2017 | 179 | 271 |
| 2018 | 170 | 310 |
| 2019 | 159 | 308 |
| 2020 | 199 | 338 |
| 2021 | 197 | 341 |
| 2022 | 181 | 349 |
| 2023 | 188 | 365 |
| 2024 | 196 | 482 |
| 2025 | 228 | 405 |
| 2026 | 108 | 250 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Anti-MS4A4A antibodies and methods of use thereof6 Oct 2026US 12,753,225 B2Alector LLC
- Compositions and methods for treating cancer6 Oct 2026US 12,753,236 B2Alpha Beta Holdings, LLC
- Construction of chimeric antigen receptor targeting CD20 antigen and activity identification of engineered T cells thereof29 Sep 2026US 12,747,279 B2Abelzeta Inc.
- IL-33 binding antibodies29 Sep 2026US 12,747,290 B2GlaxoSmithKline Intellectual Property Development Limited
- Anti-CCR8 antibodies for treating cancer29 Sep 2026US 12,747,296 B2Bristol-Myers Squibb Company
- Il-5raxcd3e t cell engaging bispecific antibody and uses thereof8 Oct 2026US 2026/0308264 A1Ajou University Industry-Academic Cooperation Foundation
- Egfr and c-met binding agent variants and methods of use1 Oct 2026US 2026/0297201 A1Janssen Biotech, Inc.
- Anti-cmet antibody1 Oct 2026US 2026/0297202 A1Pierre Fabre Medicament
- Methods of determining relative unpaired glycan content1 Oct 2026US 2026/0298943 A1Amgen Inc.
- Universal abt compounds and uses thereof24 Sep 2026US 2026/0284204 A1Kleo Pharmaceuticals, Inc.
Most cited
By later US patents
- Humanized immunoglobulins2,884US 5,585,089 AProtein Design Labs, Inc. · 1996
- Humanized immunoglobulins2,259US 5,530,101 AProtein Design Labs, Inc. · 1996
- Humanized immunoglobulins2,030US 5,693,762 AProtein Design Labs, Inc. · 1997
- Humanized immunoglobulins and methods of making the same1,467US 6,180,370 B2Protein Design Labs, Inc. · 2001
- Immunoglobulin variants1,380US 5,821,337 AGenentech, Inc. · 1998